Scarica l'app Stockscreener
30.01
1.15%
-0.35
Precedente Chiudi:
$30.36
Aprire:
$33
Volume 24 ore:
93,908
Relative Volume:
0.26
Capitalizzazione di mercato:
$2.28B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+2.88%
1M Prestazione:
-50.64%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$29.77
$34.00
Intervallo di 1 settimana:
$28.32
$38.88
Portata 52W:
$9.95
$67.00
Jyong Biotech Ltd Stock (MENS) Company Profile
Nome
Jyong Biotech Ltd
Settore
Industria
Telefono
-
Indirizzo
-
Confronta MENS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MENS
Jyong Biotech Ltd
|
30.01 | 2.31B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.17 | 109.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.61 | 82.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.12 | 56.78B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.63 | 56.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.51 | 44.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Jyong Biotech Ltd Borsa (MENS) Ultime notizie
Jyong Biotech (NASDAQ:MENS) Shares Gap UpStill a Buy? - MarketBeat
Jyong Biotech: Speculative BPH And Prostate Cancer Prevention Story (NASDAQ:MENS) - Seeking Alpha
Jyong Biotech (NASDAQ:MENS) Stock Price Down 9.6%What's Next? - MarketBeat
Taiwan's Jyong Biotech announces partnership in Korea to evaluate in‑licensing of plant-derived MCS drugs - BioSpectrum Asia
Jyong Biotech signs letter of intent with South Korean pharma company - Investing.com Nigeria
Jyong Biotech to Evaluate Licensing Deal for MCS-2 Drug Candidate in South Korea - MarketScreener
Jyong Biotech signs letter of intent with South Korean pharma company By Investing.com - Investing.com South Africa
Jyong Biotech Ltd. Signs Non‑Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In‑Licensing of Plant-Derived MCS Drugs - The Manila Times
Jyong Biotech (Nasdaq: MENS) LOI to Evaluate MCS-2 Licensing with Korean Pharma - Stock Titan
Jyong Biotech (NASDAQ:MENS) Shares Up 10.9%Should You Buy? - MarketBeat
Jyong Biotech completes primary endpoint analysis for Phase II trial of MCS-8 - Yahoo Finance
Exploring Jyong Biotech’s (NasdaqGM:MENS) Valuation Following Recent Share Price Volatility - Yahoo Finance
Jyong Biotech reports positive results for prostate cancer drug in phase II trial - Investing.com Nigeria
Jyong Biotech stock soars after positive Phase II prostate cancer drug results - Investing.com Nigeria
Jyong Biotech stock soars after positive Phase II prostate cancer drug results By Investing.com - Investing.com South Africa
Jyong Biotech Says Phase 2 Trial of MCS-8 in Prostate Cancer Meets Efficacy Endpoints - MarketScreener
Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive Outcomes - The Manila Times
Jyong Biotech (Nasdaq: MENS) MCS-8 Phase II Cuts Prostate Cancer 27%, High-Grade 17% - Stock Titan
Jyong Biotech (NASDAQ:MENS) Shares Gap DownTime to Sell? - MarketBeat
Jyong Biotech Ltd. (MENS) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Jyong Biotech is Now Oversold (MENS) - Nasdaq
Jyong Biotech plunges 49% after InvestingPro’s overvalued warning By Investing.com - Investing.com Australia
Google, Alibaba among market cap stock movers on Monday - Investing.com
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Google and Micron among market cap stock movers on Monday By Investing.com - Investing.com UK
Google and Micron among market cap stock movers on Monday - Investing.com India
Jyong Biotech (MENS US): Taiwan-Based, US-Listed, Excluded from US & Global Indices - Smartkarma
Jyong Biotech (NASDAQ:MENS) Trading Down 8%Here's Why - MarketBeat
Dow notches record-high close while tech-heavy Nasdaq slips - Yahoo Finance
Dow notches record high close, traders bet on end to shutdown - Yahoo Finance
Health insurers slide after subsidies dropped from US shutdown deal - Yahoo Finance
Global shares jump as investors eye potential end to US shutdown - Yahoo Finance
Wall Street ends higher on solid data, strong earnings - Yahoo Finance
OpenAI signs $38 billion deal to use Amazon's cloud platform - Yahoo Finance
'Hopeful' We'll Find Long-term Solution On China: Illumina CEO - Yahoo Finance
Jyong Biotech (NASDAQ:MENS) Stock Price Up 11.2%Here's What Happened - MarketBeat
FLOWSERVE CORPORATION (FLS) Stock, Price, News, Quotes, Forecast and Insights - MSN
Caterpillar Posts Upbeat Q3 Results, Joins United Therapeutics, Centene, Fortive And Other Big Stocks Moving Higher On Wednesday - Benzinga
Caterpillar, Nvidia Lead Market Cap Stock Movers on Wednesday By Investing.com - Investing.com Nigeria
Caterpillar, Nvidia Lead Market Cap Stock Movers on Wednesday - Investing.com India
Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results - Yahoo Finance
Jyong Biotech (NASDAQ:MENS) Stock Price Down 15.6%Here's Why - MarketBeat
Tesla and Nvidia lead market cap stock movers this Tuesday - Investing.com
Downgrade Sparks Sharp Fall in Jyong Biotech MENS Stock, Yet Support Holds - FXLeaders
Here's How Much Traders Expect Meta Stock To Move After Earnings This Week - Yahoo Finance
Tesla and Qualcomm Lead Monday’s Market Cap Stock Movers - Investing.com
Tesla and Qualcomm Lead Monday’s Market Cap Stock Movers By Investing.com - Investing.com UK
New Montreal Biotech LifeLore Pathways Launches to Accelerate Microbial Innovation - Yahoo Finance
Jyong Biotech's (MENS) "Sell (E+)" Rating Reaffirmed at Weiss Ratings - MarketBeat
BNB Jumps on CZ's Pardon - Yahoo Finance
Jyong Biotech Ltd Azioni (MENS) Dati Finanziari
Non sono disponibili dati finanziari per Jyong Biotech Ltd (MENS). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.76%
2.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):